Objectives: We investigated diagnostic yield of initial biopsy and repeated biopsy including apical cores. Methods: We investigated 573 consecutive men with PSA of ≤20 ng/ml who underwent prostate biopsy between 2004 and 2013. The initial 14-core biopsy consisted of the sextant type, lateral sites at the base and middle, lateral apices (la) at anterior horn sites, and apical anterior sites (aa). The repeated 18-core biopsy consisted of the initial 14-core biopsy with four transition zone (TZ) sites at the base (tzb) and middle (tzm). Results: Prostate cancer was diagnosed in 178 (38.9%) of 458 men with the initial 14-core biopsy, and 44 (38.3%) of 115 men with the repeated 18-core biopsy. In the initial biopsy setting, the unique cancer detection rate was high in apical sites (apex, la, and aa: 6.2%, 6.2% and 5.1%, respectively). In the repeated setting, it was high in the TZ site in addition to the apical site (apex, la, aa, tzm, and tzb: 6.8%, 6.8%, 11.4%, 9.1% and 11.4%, respectively). The positive SM rate at the apex was higher in patients whose cancer was detected only in sites other than the sextant region than for those in the sextant region (36.4% vs. 14.8%, P = 0.037). Conclusions: The initial 14-core and the repeated 18-core biopsy scheme including apical anterior cores are feasible for prostate cancer detection. We propose that apical biopsy cores can be used to predict not only the existence of cancer but also surgical margin status at the apex.
Introduction
For the diagnosis of prostate cancer, transrectal ultrasonography (TRUS)-guided systematic biopsy has been the standard method since Hodge et al. reported it in 1989 (1). However, this traditional sextant biopsy has a false negative rate ranging from 10% to 30% (2, 3) . Several studies demonstrated that biopsy schemes taking more cores improve the detection rate for nonpalpable cancer, and result in increased detection of T1c cancer (4) . Although the optimal protocol for prostate biopsy should be simple, effective and safe, it has not been established yet.
Surgical margin (SM) status at radical prostatectomy (RP) is an independent predictor of prognosis in patients with prostate cancer (5, 6) . The anterior side of the apex lacking the prostate capsule is the most frequent site of a positive SM (7) . Therefore, it is necessary to predict cancer extension at the apex so as not to compromise the SM status.
We investigated the diagnostic yields of initial 14-core biopsy and repeated 18-core biopsy taking apical cores. In addition, we examined whether apical cores could predict a positive SM at the apex in RP specimens.
Materials and methods
We collected biopsy data of 623 consecutive men with suspicion of prostate cancer between September 2004 and March 2013. Prostate cancer was suspected due to elevation of the serum prostate-specific antigen (PSA) level and/or abnormal findings on digital rectal examination (DRE) or TRUS. A total of 50 patients with serum PSA levels of greater than 20 ng/ml were excluded from this study. Finally, 458 men in the initial biopsy setting and 115 men in the repeated biopsy setting were enrolled in this study.
All biopsies were performed according to the methods used in our previous study (8) . The biopsy templates are shown in Fig. 1 . The initial 14-core biopsy consisted of the standard sextant biopsy, lateral mid-and lateral base sites (lm, lb), lateral apices at anterior horn sites (la), and apical anterior sites (aa). The apical anterior site was defined as the sites near the urethra at the apex of the prostate. The repeated 18-core biopsy consisted of mid-and base sites at the transition zone (TZ) (tzm, tzb) in addition to the initial 14-core biopsy scheme. A repeated biopsy was considered for several conditions: a continuously increasing PSA level, PSA density of more than 0.2 ng/ml/ml, PSA velocity of more than ≥0.75 ng/ml/year or abnormal findings of DRE (9) . Men who underwent repeated biopsy had biopsies a median of two times over 31.2 months after the initial one with a median of 10-core specimens.
In patients with prostate cancer detected by biopsy, clinical stage was determined by DRE, TRUS, abdominal computed tomography, chest X-ray and bone scanning. Magnetic resonance imaging was performed when prostatic capsular penetration was suspected. RP was considered for patients with clinically localized prostate cancer. It was done through a standard retropubic approach or a laparoscopic approach with limited pelvic lymph node dissection. Both biopsy specimens and RP specimens were histologically examined by several pathologists in one institute. The prostatectomy specimens were horizontally sectioned at 5 mm intervals. In addition, apical specimens were longitudinally sectioned at 5 mm intervals. Stage was assigned using the 2009 TNM system. A positive SM was defined as cancer tissue present at the inked specimen edge. Extraprostatic extension (EPE) was defined as cancer extension over the prostatic capsule. The outlines of tumor foci were marked on whole mount histological slides, allowing for the determination of zonal location and the calculation of tumor volume with computerassisted planimetry by using a microscope (model BZ-9000; Keyence, Osaka, Japan). Apical cancer volume was calculated in apical sections at 5 mm intervals.
We examined the diagnostic yield of extended 14-core biopsy in the initial setting and 18-core biopsy in the repeated setting. Cancer detection rates were calculated for each template with the sextant biopsy, and the sextant biopsy adding 2, 4, 6, and 8 cores from lateral and apical anterior sites (la, lm, lb, aa), in addition to 2 and 4 cores from the TZ (tzm, tzb). The rates according to the number of biopsy cores except sextant and 14 or 18 cores in the initial and repeat settings were determined by the mean ± SD of each pattern of biopsy taken. For example, the rate of cancer detection of 10 cores in the initial setting was calculated from the average of 6 biopsy patterns: sextant + la + lm, sextant + la + lb, sextant + la + aa, sextant + lm + lb, sextant + lm + aa, and sextant + lb + aa. We set the cancer detection rates of the initial 14-core biopsy and the repeated 18-core biopsy at 100%, and calculated the percentage permitting detection of prostate cancer (%PDC). The most efficient number of cores was defined as the smallest number that permitted a %PDC of more than 95% (10) . In addition, the overall and unique cancer detection rates according to biopsy site were Figure 1 . The figure shows a schematic drawing of the 14-core sites in the initial biopsy setting and 18-core sites in the repeated biopsy setting in coronal (a), transverse (b), and sagittal (c) sections. In the initial biopsy, 14 cores were taken from the peripheral zone including standard sextant cores (a, m, b), 3 cores (la, lm, lb) from the lateral region and 1 core (aa) from the apical anterior region in each side. In the repeated biopsy, 2 cores (tzm, tzb) were taken from the transition zone (TZ) in each side in addition to the initial 14-core biopsy, making a total of 18 cores.
evaluated. The unique cancer detection rate was calculated only in patients with prostate cancer. Pathological findings of RP specimens were compared between positive cores in the sextant region (sextant group) and cores that were negative in the sextant region but positive in the extra-sextant region (extended group).
Several clinicopathological factors were analyzed using the chisquare test, Fisher's exact test or Mann-Whitney U test. After surgery, serum PSA measurement was performed every 3 months throughout the follow-up period. PSA relapse was defined as an increase of undetectable PSA (0.2 ng/ml) to 0.2 ng/ml or greater. If the patients failed to achieve undetectable PSA levels after RP, the time to PSA relapse was defined as 0 days. PSA relapse-free survival rates were calculated using the Kaplan-Meier method, and the differences in survival were assessed by the log-rank test. The Cox proportional hazards model was used to estimate the risk of PSA relapse. A P value of <0.05 was considered to be statistically significant. All statistical analyses were performed with EZR, which is a graphical user interface for R (version 2.13.0; The R Foundation for Statistical Computing, Vienna, Austria).
Results
Prostate cancer was diagnosed in 178 (38.9%) of 458 men with the initial 14-core biopsy, and 44 (38.3%) of 115 men with the repeated 18-core biopsy. In the initial biopsy, patients with cancer were older, and had a higher PSA level, higher positive DRE, higher positive TRUS findings and smaller prostate volume than those without cancer (Table 1 ). In the repeated biopsy, patients with cancer had higher positive TRUS findings and smaller prostate volume than those without cancer.
The cancer detection rate was evaluated according to the number of biopsy cores. In the initial biopsy, the cancer detection rate was decreased with fewer biopsy cores (Fig. 2a) . It was significantly decreased in biopsies with 10 or fewer cores (P < 0.05). Similar results were observed in the repeated biopsy (Fig. 2b) . Biopsies with 14 or fewer cores had a lower detection rate than 18-core biopsy (P < 0.05).
We evaluated the most efficient number of cores by calculating %PDC according to the PSA level, DRE findings, and prostate volume. In the initial biopsy, the most efficient numbers of cores were 14 for men with prostate volume ≥35 ml, 12 for those with regardless of PSA level, negative DRE or prostate volume of <35 ml, and 10 for those with positive DRE (Fig. 3a-c) . In the repeated biopsy, they were 18 cores for men with PSA of <10 ng/ml, negative DRE or prostate volume of <35 ml, 16 for men with PSA of 10-20 ng/ml, or prostate volume of ≥35 ml, and eight for those with positive DRE (Fig. 3d-f) .
The site-specific overall and unique cancer detection rates are shown in Table 2 . In the initial biopsy, cancer was frequently found in apical (a, la, aa) and middle (m) sites. The unique cancer detection rate was high in apical (a, la, aa) sites. In the repeated biopsy, the unique cancer detection rate was high in the TZ site in addition to the apical site.
Of 573 men who received biopsy, macrohematuria, difficult urination, urinary retention and rectal bleeding occurred in 141 (24.6%), 21 (3.7%), 4 (0.7%) and 4 (0.7%), respectively. Hemospermia was rarely observed (0.2%). Six men (1.0%) had fever (≥38°C) because of acute prostatitis. Hospitalization was required for four men with urinary retention and three men with fever. None had sepsis. There was no significant difference in the frequency of complications between the initial biopsy setting and the repeated biopsy setting. Of 222 patients with prostate cancer, 76 (34.2%) underwent RP without neoadjuvant therapy. No patients with a cancer volume of <0.5 ml were observed. The incidence of a positive SM at the apex was significantly higher in the extended group than in the sextant group (36.4% vs. 14.8%, P = 0.037) ( Table 3) . During the median follow-up period of 82.6 months, 19 patients (25.0%) developed PSA relapse. In 69 patients who had apical tumor, the patients with positive SMs had greater risk of PSA relapse than those with negative SMs (HR 2.88, 95%CI 1.17-7.09, P = 0.022). However, in the subgroup of patients with positive SMs, there was no difference in PSA relapse between the extended group and the sextant group. In addition, there was no significant difference in the mean apical tumor volume between the extended and sextant groups (0.527 ml cores (a, b) . Cancer detection rates were calculated for each template with sextant biopsy, sextant biopsy adding 2, 4, 6, and 8 cores from lateral and apical anterior sites (la, lm, lb, aa), and 2 and 4 cores from TZ (tzm, tzb). (a) In the initial 14-core biopsy, cancer detection rates for 14 and 20.0%, respectively. They were significantly lower for with 12 or fewer cores. Data are means; bars, ± SD. *, significantly different from 18-core biopsy (P < 0.05, one-way ANOVA using Dunnett's correction). † sextant + lateral and apical anterior sites (la, lm, lb, aa), ‡ sextant + three of four sites (la, lm, lb, aa), § sextant + two of four sites (la, lm, lb, aa), ∥ sextant + one of four sites (la, lm, lb, aa), ¶ sextant, ** sextant + four sites (la, lm, lb, aa) + two TZ sites (tzm, tzb), † † sextant + four sites (la, lm, lb, aa) + one of two TZ sites (tzm, tzb). vs. 0.622 ml, P = 0.652). The median maximal diameter of the tumor in the apex was 9.6 mm in the extended group compared with 12.9 mm in the sextant group (P = 0.176).
Discussion
An ideal biopsy scheme to detect only clinically significant cancer requires easy performance, a high cancer detection rate, and a low complication rate. We analyzed the performance of initial 14-core biopsy and repeated 18-core biopsy by the TRUS-guided transrectal approach. The overall diagnostic yields were 38.9% and 38.3% in the initial and the repeated settings, respectively, similar to recent extended biopsy series (11, 12) . We evaluated the smallest numbers of efficient cores for the initial and repeated biopsies. Our results demonstrated that at least 12-or 16-core biopsy was needed according to the PSA level, DRE, or prostate volume in the initial biopsy. However, irrespective of clinical findings, uniform 14-core biopsy including apical cores seems to be practical, especially to predict the SM status of surgical specimens as described below. In the repeated biopsy, 18 cores were required for men with PSA of <10 ng/ml, negative DRE or prostate volume of <35 ml who underwent prior 10-core biopsy.
As well as number of cores, it is important to consider the location in which prostate cancer is most likely to exist. Extended biopsies adding cores from these sites resulted in increased detection rates (11) (12) (13) (14) . In mapping of the cancer distribution in RP specimens, nonpalpable prostate cancers were frequently found in the anterior half of the gland at the apex to mid-prostate levels (15) . Moreover, several studies demonstrated that apical anterior cores were useful for cancer detection (16) (17) (18) . In the present study, cancer was frequently detected in the apex to middle sites. The cancer detection rate was particularly high in apical core sites (a, la, aa) both in the initial and repeated biopsy settings. These results suggest that additional cores should be taken from lateral apex and apical anterior sites in the extended biopsy protocol both in the initial and repeated biopsy settings.
Since TZ biopsy increases the cancer detection rate only from 0.5% to 3.0%, it is not recommended in the initial setting (19) . Previously, we reported the results of transrectal 6-core biopsy from the PZ and transperineal 2-core biopsy from the TZ. No cancers were detected in the TZ alone (20) . In contrast, Ishizuka et al. reported that the cancer detection rate in the TZ alone was relatively high (8%) with transrectal sextant and four additional TZ biopsies (21) . Thus, obtaining more cores from the TZ could achieve a better cancer detection rate, although further studies are needed to standardize the method of TZ biopsy in the initial setting. In this study, unique cancer detection rates for the TZ were 9.1% in tzm and 11.4% in tzb on the repeated biopsy. Moreover, the 16-core scheme, which included only two cores from the TZ in addition to the initial 14-core biopsy, did not achieve detection of 95% of the prostate cancer in men with PSA of <10 ng/ml, negative DRE or prostate volume of <35 ml. Thus, taking 4 cores for TZ biopsy might be required in the repeat setting.
In the present study, 141 (24.6%) men had macrohematuria, which was quite high compared with the 12.9% found in a nationwide survey in Japan (22) . These different results may be explained by our biopsy protocol taking the apical anterior cores near the urethra. However, macrohematuria spontaneously resolved without intervention. Other complication rates were similar to those in previous reports (22, 23) .
Our extended biopsy scheme showed an association between the existence of cancer and SM status at the apex. Pathological findings of RP specimens showed that patients examined only by the extended scheme had a more positive SM at the apex than those with the sextant scheme. However, there was no significant difference in the apical tumor volume and the maximal diameter between the groups. These results suggested that cancer existed close to the surgical resection line at the apex in patients examined by the extended scheme. We demonstrated that a positive SM was a predictive factor of PSA relapse regardless of the extended or the sextant biopsy scheme. The 7-year PSA relapse-free survival in patients with positive SMs was 58.2% compared with 81.7% in those with negative SMs (P = 0.002) (data not shown). Thus, we propose that preoperative information from apical cores (aa, la) is very important to avoid a positive SM when performing a nerve-sparing procedure or manipulation of the apex. Previously, we developed a simple algorithm for decision-making on neurovascular bundle preservation based on the apical core characteristics, clinical T stage, preoperative PSA level and Gleason score (24) . In this study, the incidence of positive SMs was observed in 10 (8.7%) of 115 prostate sides in the favorable algorithm group. When this algorithm was combined with surgeon's intraoperative assessments, the incidence of positive SMs was only 2.1% in neurovascular bundle preservation sides. Thus, neurovascular bundle preservation could be achieved without affecting SM status by using this algorithm even in patients with apical tumor examined by the extended scheme.
We investigated the usefulness of initial 14-core biopsy and repeated 18-core biopsy with apical cores. However, the present study had some limitations. The total number of patients involved in the study was relatively small. In men with the repeated biopsy, the total number and the locations of the initial biopsy cores varied because the majority underwent the initial biopsy in other clinics. RP specimens were evaluated only for 76 patients (34.2%) with prostate cancer. However, we believe that the present biopsy scheme is simple, safe, and feasible for a good diagnostic yield.
Conclusions
The initial 14-core and repeated 18-core biopsy scheme including apical anterior cores is simple, safe and feasible for cancer detection. We propose that apical biopsy cores can be used to predict not only the existence of cancer but also the SM status at the apex. This information could help in nerve-sparing procedures and manipulation of the apex.
